Descriptions

The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.

Autoinhibitory domains (AIDs)

Target domain

Relief mechanism

Assay

cis-regPred

Accessory elements

No accessory elements

Autoinhibited structure

Activated structure

1 structures for Q18331

Entry ID Method Resolution Chain Position Source
AF-Q18331-F1 Predicted AlphaFoldDB

No variants for Q18331

Variant ID(s) Position Change Description Diseaes Association Provenance
No variants for Q18331

No associated diseases with Q18331

3 regional properties for Q18331

Type Name Position InterPro Accession
domain Protein kinase domain 562 - 888 IPR000719
domain Adenylyl cyclase class-3/4/guanylyl cyclase 923 - 1135 IPR001054
domain Serine-threonine/tyrosine-protein kinase, catalytic domain 640 - 884 IPR001245

Functions

Description
EC Number 4.6.1.2 Phosphorus-oxygen lyases
Subcellular Localization
  • Cell membrane ; Single-pass type I membrane protein
PANTHER Family
PANTHER Subfamily
PANTHER Protein Class
PANTHER Pathway Category No pathway information available

2 GO annotations of cellular component

Name Definition
integral component of membrane The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
plasma membrane The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

6 GO annotations of molecular function

Name Definition
ATP binding Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator.
GTP binding Binding to GTP, guanosine triphosphate.
guanylate cyclase activity Catalysis of the reaction: GTP = 3',5'-cyclic GMP + diphosphate.
metal ion binding Binding to a metal ion.
peptide receptor activity Combining with an extracellular or intracellular peptide to initiate a change in cell activity.
protein kinase activity Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.

5 GO annotations of biological process

Name Definition
cGMP biosynthetic process The chemical reactions and pathways resulting in the formation of cyclic GMP, guanosine 3',5'-phosphate.
intracellular signal transduction The process in which a signal is passed on to downstream components within the cell, which become activated themselves to further propagate the signal and finally trigger a change in the function or state of the cell.
protein phosphorylation The process of introducing a phosphate group on to a protein.
receptor guanylyl cyclase signaling pathway The series of molecular signals initiated by an extracellular ligand binding to a receptor on the surface of the target cell where the receptor possesses guanylyl cyclase activity, and ending with the regulation of a downstream cellular process, e.g. transcription.
signal transduction The cellular process in which a signal is conveyed to trigger a change in the activity or state of a cell. Signal transduction begins with reception of a signal (e.g. a ligand binding to a receptor or receptor activation by a stimulus such as light), or for signal transduction in the absence of ligand, signal-withdrawal or the activity of a constitutively active receptor. Signal transduction ends with regulation of a downstream cellular process, e.g. regulation of transcription or regulation of a metabolic process. Signal transduction covers signaling from receptors located on the surface of the cell and signaling via molecules located within the cell. For signaling between cells, signal transduction is restricted to events at and within the receiving cell.

17 homologous proteins in AiPD

UniProt AC Gene Name Protein Name Species Evidence Code
P46197 NPR2 Atrial natriuretic peptide receptor 2 Bos taurus (Bovine) PR
O02740 GUCY2F Retinal guanylyl cyclase 2 Bos taurus (Bovine) PR
P51841 GUCY2F Retinal guanylyl cyclase 2 Homo sapiens (Human) PR
Q02846 GUCY2D Retinal guanylyl cyclase 1 Homo sapiens (Human) PR
P20594 NPR2 Atrial natriuretic peptide receptor 2 Homo sapiens (Human) PR
P52785 Gucy2e Retinal guanylyl cyclase 1 Mus musculus (Mouse) PR
Q6VVW5 Npr2 Atrial natriuretic peptide receptor 2 Mus musculus (Mouse) PR
Q5SDA5 Gucy2f Retinal guanylyl cyclase 2 Mus musculus (Mouse) PR
P51840 Gucy2e Retinal guanylyl cyclase 1 Rattus norvegicus (Rat) PR
P18910 Npr1 Atrial natriuretic peptide receptor 1 Rattus norvegicus (Rat) PR
P16067 Npr2 Atrial natriuretic peptide receptor 2 Rattus norvegicus (Rat) PR
P51842 Gucy2f Retinal guanylyl cyclase 2 Rattus norvegicus (Rat) PR
Q09435 gcy-1 Receptor-type guanylate cyclase gcy-1 Caenorhabditis elegans PR
Q10029 gcy-2 Receptor-type guanylate cyclase gcy-2 Caenorhabditis elegans PR
Q23682 gcy-5 Receptor-type guanylate cyclase gcy-5 Caenorhabditis elegans PR
O16544 gcy-19 Receptor-type guanylate cyclase gcy-19 Caenorhabditis elegans PR
X5M8U1 gcy-17 Receptor-type guanylate cyclase gcy-17 Caenorhabditis elegans PR
10 20 30 40 50 60
MPCREIFLLW ILVPIASSSD HITFFGRYAC NVDFKTDYCT PDTYVGRAFY YGLEDGGGIT
70 80 90 100 110 120
TNGTFVNSDI TVEFFDPTVQ GNFSIGRQDG NYMSSMLDIM LADTKKNDGL LGVVGVENDC
130 140 150 160 170 180
KEIAALAQAY DASSLLVNCE DQVGESQMPS STALQMSSTQ GGKYRAFAKL AKSVGWNNLA
190 200 210 220 230 240
VINFVEDGPA DISYHDQLLD ALSAESISLD FVKKGGFSST ITSAMFTGLE SVIDVILETY
250 260 270 280 290 300
MKTRIYVIVL DLPVSGTFFM NAMSTMGLLE TGKYFVVMMS SIESDAANYF GFNVNRGNMI
310 320 330 340 350 360
FKTIDYGISD ADIRQYYRSF MYFTDVPHYT KDFSDEWTSF QKRVDGDASK TFCPPMCNTK
370 380 390 400 410 420
AKGIANNDPW SDDAYWYSES PSIVDAYDLG RLLSETVKVH GASLLRDPES LVQTMSGRGV
430 440 450 460 470 480
TSLLGYVTKF NTNGVSQREY ILWAPQQASS SNGPIPLPEW ATLAARMLPD GKGNYSIIWK
490 500 510 520 530 540
NLTQLGIFNG ELPQSKPECG FNNELCPAGI RNLSELEIIV IAVCVVAILI LVGVIAYIAR
550 560 570 580 590 600
WIAYERRLES SYFLVHRKHV QLVDMTKFGS SRGGSMIQSA MSMRSQYEDS GPVGGATMNF
610 620 630 640 650 660
YTNGIRKAAI RRNQMQRSDK GPAANRDEWL EIVDWHLAKY ENTLVTVRKI NKTQLKLTRE
670 680 690 700 710 720
MKQEIDLLMN ETHENLNRFF GLINESDLIF TIHSYGPRKS LMDLLRNDDL RLDRMFKVSF
730 740 750 760 770 780
VEDVVKGLQF LHEGSKIGYH GNLKSSNCIV DAYWRIKLSN YGMEQIRVEE PESKPDDLLW
790 800 810 820 830 840
FAPEIIRRYA VKHDLSKLEL AKADIYSLAI VLYEIYGRQG PFGDDLLDSD EIIEQLKFPD
850 860 870 880 890 900
GGALTRPDIH LITKAPYPLA SVVEKCWVED PASRPSIKKV RELLKPLSKG LKGNIADNIM
910 920 930 940 950 960
NLLDRYRNNL EDVIKERTEQ LEDERKRNES LLLQLLPKSV ANSLKNGQPV DAEFYDSVSI
970 980 990 1000 1010 1020
YFSDIVGFTA LSSKSTPLQV VNMLNNLYTN FDTIIDKFDC YKVETIGDAY MFVSGLPEVN
1030 1040 1050 1060 1070 1080
SYLHAGEVAS ASLELLDSIK TFTVSHCPDE KLRLRIGNHT GPVVTGVVGI RMPRYCLFGD
1090 1100 1110 1120 1130 1140
TVIIANMMES SGEPMRIQIS SDAYELILKC GGYVTEQREK IVLKNKLEVM TYWMNDYSKD
1150 1160
ARLARLVAHQ EKFPHLEHLI HKFNKGVR